Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

Turk J Vasc Surg. 2023; 32(1): 42-50


A comparative analysis of DOACs Vs warfarin for venous thromboembolism treatment in renal insufficiency

Ozlem Balcioglu, Natacha Usanase, Berna Uzun, Ilker Ozsahin, Dilber Uzun Ozsahin.




Abstract

Aim: Annually, millions of people die from kidney diseases making it a serious public health concern. Patients with renal insufficiency have hemostatic defects that enhance their risk of thrombosis and bleeding. Evaluating the advantages and hazards of anticoagulant thromboprophylaxis is challenging.
Material and Methods: By using the fuzzy preference ranking organization method for enrichment evaluation (fuzzy PROMETHEE) and fuzzy multi-criteria optimization and compromise solution (fuzzy VIKOR), which are analytical multi-criteria decision-making (MCDM) techniques, this study aims to analyze diverse types of anticoagulants; specifically, Vitamin K-Antagonist (warfarin) and direct oral anticoagulants namely; Dabigatran, Rivaroxaban, Apixaban, and Edoxaban, by considering various criteria.
Results: Direct oral anticoagulants outperformed warfarin in terms of safety and effectiveness. Among all the analyzed anticoagulants, Apixaban was found to be the best-ranked anticoagulant with both fuzzy PROMETHEE and fuzzy VIKOR, with a net flow of 0.0064 and the lowest Qj value of 0.0000, respectively, compared with other alternatives depending on the selected criteria while warfarin was found to be the least ranked anticoagulant with a net flow of -0.0043 and the highest number of Qj being 1, respectively.
Conclusion: The MCDM techniques used were effective, highly accurate, and sensitive in the comparison of anticoagulant therapy for venous thrombosis in renal insufficiency based on the chosen criteria. The proper use of a safe and effective anticoagulant will boost better performance not only in patients’ survival and well-being but also in the health care center.

Key words: Direct oral anticoagulants, fuzzy logic, PROMETHEE, renal insufficiency, VIKOR






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.